Lung Cancer
Conditions
Interventions
A:0.33% ropivacaine block on the anterior serratus muscle plane
B:0.33% ropivacaine block on the anterior serratus muscle plane + 20 mg esketamine
C:0.33% ropivacaine block on the anterior serratus muscle plane + 30 mg esketamine
Sponsors
the First Affiliated Hospital of Hebei North University
Eligibility
Sex/Gender
All
Age
45 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Patients who plan to undergo thoracoscopic lung cancer with concomitant coronary heart disease; (2) ASA grade II-III, age>45 years but<75 years old; BMI (18-25) kg/m2; Surgical time is 2-4 hours; (3) NYHA classification level I to II; (4) Patients undergoing elective surgery must have their endotracheal tube removed after surgery.
Exclusion criteria
Exclusion criteria: (1) Individuals who are known to be allergic to ketamine and other medications used in this study; (2) Individuals who have experienced angina and severe heart failure in the past three months; (3) Patients with severe liver, kidney or metabolic diseases before surgery; (4) Patients with sinus bradycardia and cardiac conduction system block; (5) Severe electrolyte imbalance and acid-base imbalance; (6) Long term use of sedative or psychiatric drugs; (7) Intraoperative bleeding volume>800ml, excluding cases exceeding 20% of circulating blood volume; (8) Not willing to accept the operator of this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| First wake-up time;High-sensitivity cardiac troponin T ;Cardiac troponin T ;High-sensitivity C-reactive protein;Interleukin-6;Interleukin-10;Vas score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event ; | — |
Countries
China
Contacts
Public ContactChen Yanlin
First Affiliated Hospital of Hebei North University
Outcome results
None listed